D. B. Longely and P. G. Johnston, Molecular mechanisms of drug resistance, The Journal of Pathology, vol.1603, issue.2, pp.275-292, 2005.
DOI : 10.1002/path.1706

M. M. Gottesman, Mechanisms of Cancer Drug Resistance, Annual Review of Medicine, vol.53, issue.1, pp.615-627, 2002.
DOI : 10.1146/annurev.med.53.082901.103929

R. B. Weiss, The anthracyclines: will we ever find a better doxorubicin?, Semin. Oncol, vol.19, pp.670-686, 1992.

D. Nielsen, C. Maare, and T. Skovsgaard, Cellular resistance to anthracyclines, General Pharmacology: The Vascular System, vol.27, issue.2, pp.251-255, 1996.
DOI : 10.1016/0306-3623(95)02013-6

M. Binashi, M. Bigioni, A. Cipollone, C. Rossi, C. Goso et al., Anthracyclines: Selected New Developments, Current Medicinal Chemistry-Anti-Cancer Agents, vol.1, issue.2, pp.113-130, 2001.
DOI : 10.2174/1568011013354723

M. M. Gottesman and I. Pastan, Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter, Annual Review of Biochemistry, vol.62, issue.1, pp.385-427, 1993.
DOI : 10.1146/annurev.bi.62.070193.002125

U. Massing and S. Fuxius, Liposomal formulations of anticancer drugs: selectivity and effectiveness, Drug Resistance Updates, vol.3, issue.3, pp.171-177, 2000.
DOI : 10.1054/drup.2000.0138

M. Ruby, C. Konak, and K. Ulbrich, Polymeric micellar pH-sensitive drug delivery system for doxorubicin, J. Control Release, pp.137-148, 2005.

F. Tewes, E. Munnier, B. Antoon, O. L. Nagaboni, J. S. Cohen et al., Comparative study of doxorubicinloaded poly(latide-co-glycolide) nanoparticles prepared by single and double emulsion methods, Eur, J. Pharm. Biopharm, pp.2-016, 2007.

G. D. Stefano, M. Lanza, F. Kraz, L. Merina, and L. Fiume, A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate, European Journal of Pharmaceutical Sciences, vol.23, issue.4-5, pp.393-397, 2004.
DOI : 10.1016/j.ejps.2004.09.005

G. , D. Stefano, L. Fiume, M. Domenicali, C. Busi et al., Doxorubicin coupled to lactosaminated albumin: effect on rats with liver fibrosis and cirrhosis, pp.38-404, 2006.

M. Zorko and U. , Cell-penetrating peptides: mechanism and kinetics of cargo delivery, Advanced Drug Delivery Reviews, vol.57, issue.4, pp.529-545, 2005.
DOI : 10.1016/j.addr.2004.10.010

D. Derossi, A. H. Joliot, G. Chassaing, and A. Prochiantz, The third helix of the Antennapedia homeodomain translocates through biological membranes, J. Biol. Chem, vol.269, pp.10444-10450, 1994.

D. Derossi, G. Chassaing, and A. Prochiantz, Trojan peptides: the penetratin system for intracellular delivery, Trends in Cell Biology, vol.8, issue.2, pp.84-87, 1998.
DOI : 10.1016/S0962-8924(98)80017-2

K. Henning, M. Natisha, J. I. Richard, and M. S. Kathryn, Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin, Anticancer Drugs, vol.18, pp.419-425, 2007.

R. Sharma, L. Arnold, and K. S. Gulliya, Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells, Anticancer Res, vol.15, pp.295-304, 1995.

H. M. Coley, Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer, Cancer Treatment Reviews, vol.34, issue.4, pp.378-390, 2008.
DOI : 10.1016/j.ctrv.2008.01.007

S. Aroui, N. Ram, F. Appaix, M. Ronjat, A. Kenani et al., Maurocalcine as a Non Toxic Drug Carrier Overcomes Doxorubicin Resistance in the Cancer Cell Line MDA-MB 231, Pharmaceutical Research, vol.106, issue.Pt 4, pp.1007-11095, 2008.
DOI : 10.1007/s11095-008-9782-1
URL : https://hal.archives-ouvertes.fr/inserm-00356481

L. C. Beck and . Erickson, Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells, J. Pharmacol. Exp. Ther, vol.324, pp.95-102, 2008.

J. Temsamani and P. Vidal, The use of cell-penetrating peptides for drug delivery, Drug Discovery Today, vol.9, issue.23, pp.1012-1019, 2004.
DOI : 10.1016/S1359-6446(04)03279-9

K. Saar, M. Lindgren, M. Hansen, E. Eiríksdóttir, Y. Jiang et al., Cell-penetrating peptides: A comparative membrane toxicity study, Analytical Biochemistry, vol.345, issue.1, pp.55-65, 2005.
DOI : 10.1016/j.ab.2005.07.033

M. Mazel, P. Clair, C. Rousselle, P. Vidal, J. M. Scherrmann et al., Doxorubicin-peptide conjugates overcome multidrug resistance, Anti-Cancer Drugs, vol.12, issue.2, pp.107-116, 2001.
DOI : 10.1097/00001813-200102000-00003

C. Castex, P. Merida, E. Blanc, P. Clair, A. R. Rees et al., 2-Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance, Anti-Cancer Drugs, vol.15, issue.6, pp.609-617, 2004.
DOI : 10.1097/01.cad.0000132231.28888.fa

M. Mae and U. , Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery, Current Opinion in Pharmacology, vol.6, issue.5, pp.509-514, 2006.
DOI : 10.1016/j.coph.2006.04.004

Y. Van-hensbergen, H. J. Broxterman, Y. W. Elderkamp, J. Lankelma, J. C. Beers et al., A doxorubicin???CNGRC-peptide conjugate with prodrug properties, Biochemical Pharmacology, vol.63, issue.5, pp.63-897, 2002.
DOI : 10.1016/S0006-2952(01)00928-5

G. A. Gusarova, I. C. Wang, M. L. Major, V. V. Kalinichenko, T. Ackerson et al., A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment, Journal of Clinical Investigation, vol.117, issue.1, pp.99-111, 2007.
DOI : 10.1172/JCI27527

M. Hirose, M. Takatori, Y. Kuroda, M. Abe, E. Murata et al., Effect of Synthetic Cell-Penetrating Peptides on TrkA Activity in PC12 Cells, Journal of Pharmacological Sciences, vol.106, issue.1, pp.107-113, 2008.
DOI : 10.1254/jphs.FPZ070263